Stay updated on Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page.

Latest updates to the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page
- Check5 days agoChange DetectedUPMC Hillman Cancer Center was added as a participating site, and the University of Pittsburgh Cancer Institute (UPCI) was removed. The study record revision was updated to version v3.7.0 (from v3.6.6).SummaryDifference0.2%

- Check13 days agoNo Change Detected
- Check19 days agoChange DetectedThe page now displays Revision: v3.6.6, indicating a new build behind the scenes. No study content or navigation changes are indicated.SummaryDifference0.0%

- Check33 days agoChange DetectedDate entries were added and older dates removed in the study record, updating the trial timeline and reporting milestones. These updates reflect administrative changes to scheduling and documentation rather than the study's scientific content.SummaryDifference0.2%

- Check40 days agoChange DetectedRevision tag updated from v3.6.4 to v3.6.5 on the page, signaling a small update to the site. This change does not modify the study details or visible content.SummaryDifference0.0%

- Check62 days agoChange DetectedThe page revision tag was updated from v3.6.3 to v3.6.4, signaling a small update to the page version.SummaryDifference0.0%

- Check83 days agoChange DetectedThe page revision tag was updated from v3.6.0 to v3.6.3. This change reflects a newer build of the page content rather than a substantive modification.SummaryDifference0.0%

Stay in the know with updates to Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page.